Table 1 Pretreatment patient characteristics.

	Glembatumumab vedotin (n = 218)		Capecitabine (n = 109)		All patients (n = 327)
	No.	%	No.	%	No.	%
Age, years
Median	55		55		55
Range	28–85		31–85		28–85
ECOG performance status
0	106	49	60	55	166	51
1	111	51	47	43	158	48
2	1	1	1	1	2	1
Unknown	0	0	1	1	1	<1
Visceral disease^a	173	79	80	73	253	77
Duration of disease since initial diagnosis of breast cancer, years
Median	2.5		2.3		2.4
Range^b	0.3–30.9		0.3–35.3		0.3–35.3
Duration of metastatic disease, years
Median	0.6		0.6		0.6
Range	0–8.0		0–3.4		0–8.0
Historic or current CNS involvement	20	9	6	6	26	8
Receptor status for metastatic disease^c
Triple negative (ER, PR, HER2)	216	99	108	99	324	99
ER/PR < 1%	189	87	98	90	287	88
ER/PR 1–9%	28	13	11	10	39	12
gpNMB expression by IHC^d
<25%			1	1	1	<1
25–49%	78	36	43	39	121	37
50–<75%	69	32	29	27	98	30
75–100%	71	33	36	33	107	33
No. of prior anticancer regimens^e
Median	2		2		2
Range	1–5		1–5		1–5

ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, gpNMB glycoprotein NMB.
^aVisceral disease: tumor in lung, liver, spleen, esophagus, stomach, small intestine, colon, rectum, omentum, peritoneum, kidney, pancreas, or adrenal gland.
^bTime from initial diagnosis of breast cancer, including patients who were not triple-negative at the time or whose receptor status was unknown.
^cTriple-negative status was unknown for two patients in the glembatumumab vedotin arm and one patient in the capecitabine arm. ER/PR % positivity was unknown for one patient in the glembatumumab vedotin arm.
^dgpNMB: based on % expression in malignant epithelial cells from the last sample before first dose of study drug. The highest expression is reported there was ≥1 sample collected with the same date.
^eIncluding hormonal therapies.

Quick links

Search